Gene: Sparc (secreted protein acidic and cysteine rich) Rattus norvegicus
Analyze
Symbol:
Sparc
Name:
secreted protein acidic and cysteine rich
Description:
Exhibits calcium ion binding activity. Involved in several processes, including animal organ development; response to L-ascorbic acid; and response to lead ion. Localizes to several cellular components, including extracellular space; glutamatergic synapse; and vesicle. Biomarker of diabetic angiopathy; membranoproliferative glomerulonephritis; membranous glomerulonephritis; myocardial infarction; and stomach carcinoma. Human ortholog(s) of this gene implicated in cervix carcinoma; endometrial carcinoma; and osteogenesis imperfecta type 17. Orthologous to human SPARC (secreted protein acidic and cysteine rich); INTERACTS WITH 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine; 1-naphthyl isothiocyanate; 17alpha-ethynylestradiol.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
basement-membrane protein 40; BM-40; ON; osteonectin; Secreted acidic cystein-rich glycoprotein (osteonectin); secreted acidic cysteine rich glycoprotein; secreted protein acidic and rich in cysteine; secreted protein, acidic, cysteine-rich (osteonectin)
Orthologs:
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
SPARC (secreted protein acidic and cysteine rich) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther
Mus musculus (house mouse):
Sparc (secreted acidic cysteine rich glycoprotein) HGNC
EggNOG, OrthoMCL, NCBI, OMA, HomoloGene, Inparanoid, Panther, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Sparc (secreted protein acidic and cysteine rich) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
SPARC (secreted protein acidic and cysteine rich) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
SPARC (secreted protein acidic and cysteine rich) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Sparc (secreted protein acidic and cysteine rich) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
SPARC (secreted protein acidic and cysteine rich) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Chlorocebus sabaeus (African green monkey):
SPARC (secreted protein acidic and cysteine rich) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Heterocephalus glaber (naked mole-rat):
Sparc (secreted protein acidic and cysteine rich) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Alliance orthologs 3
Mus musculus (house mouse):
Sparc (secreted acidic cysteine rich glycoprotein)
Alliance
DIOPT (PANTHER|Ensembl Compara|OMA|OrthoFinder|InParanoid|OrthoInspector|Hieranoid)
Homo sapiens (human):
SPARC (secreted protein acidic and cysteine rich)
Alliance
DIOPT (PANTHER|HGNC|Ensembl Compara|OMA|OrthoFinder|InParanoid|OrthoInspector|Hieranoid)
Danio rerio (zebrafish):
sparc (secreted protein, acidic, cysteine-rich (osteonectin))
Alliance
DIOPT (PANTHER|OrthoFinder|InParanoid|OrthoInspector|Hieranoid)
Caenorhabditis elegans (roundworm):
ost-1
Alliance
DIOPT (PANTHER|Ensembl Compara|OMA|OrthoFinder|InParanoid|OrthoInspector|Hieranoid)
Drosophila melanogaster (fruit fly):
SPARC
Alliance
DIOPT (PANTHER|Ensembl Compara|OMA|OrthoFinder|InParanoid|OrthoInspector|Hieranoid)
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 10 40,742,390 - 40,764,232 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 10 40,742,400 - 40,764,185 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 10 40,573,510 - 40,595,261 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 10 40,809,730 - 40,831,481 (-) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 10 40,823,352 - 40,845,104 (-) NCBI Celera 10 38,848,158 - 38,869,906 (-) NCBI Celera Cytogenetic Map 10 q22 NCBI RH 3.4 Map 10 414.6 RGD
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Disease Annotations
RGD Manual Annotations
Brain Injuries IEP 2300066 mRNA:increased expression:brain, blood vessel RGD calcinosis ISO RGD:731035 9068449 protein:increased expression:dermis: RGD cervix carcinoma ISO RGD:731035 2300022 DNA:hypermethylation RGD diabetic angiopathy IEP 2300063 associated with Diabetes Mellitus, Experimental, mRNA, protein:increased expression:mesentery, blood vessel RGD Diabetic Nephropathies IEP 2300072 associated with Diabetes Mellitus, Experimental, mRNA, protein:decreased expression:kidney RGD endometrial carcinoma ISO RGD:731035 2300020 DNA, mRNA, protein:hypermethylation, altered expression RGD Endotoxemia IEP 2300026 mRNA, protein:decreased expression:kidney RGD Experimental Liver Cirrhosis IMP 2300030 RGD Experimental Liver Cirrhosis IEP 2300071 mRNA:increased expression:liver, fat cell RGD Inflammation ISO RGD:11336 2300051 associated with Hypertension RGD membranoproliferative glomerulonephritis IEP 2300070 mRNA:increased expression:glomerulus RGD membranous glomerulonephritis IEP 2300069 protein:increased expression:kidney RGD myocardial infarction IEP 2300056 mRNA:increased expression:heart RGD obesity ISO RGD:11336 2300062 mRNA:increased expression:adipose tissue RGD Ovarian Neoplasms ISO RGD:11336 2300019 RGD ovary epithelial cancer ISO RGD:731035 2300027 mRNA, protein:increased expression:stromal cell RGD progressive osseous heteroplasia ISO RGD:731035 9068449 protein:increased expression:dermis: RGD pulmonary fibrosis ISO RGD:11336 30309204 associated with Middle East respiratory syndrome, mRNA:increased expression:lung: RGD renal cell carcinoma ISO RGD:731035 2300025 mRNA, protein:increased expression:kidney RGD Spinal Cord Injuries ISO RGD:11336 2300052 RGD stomach carcinoma IEP 2300058 mRNA:increased expression:stomach mucosa RGD urinary bladder cancer ISO RGD:731035 2300021 RGD urinary bladder cancer disease_progression ISO RGD:731035 2300024 RGD Wounds and Injuries IEP 2300076 mRNA, protein:increased expression:skin, fibroblast RGD
Imported Annotations - ClinVar
Hereditary Neoplastic Syndromes ISO RGD:731035 8554872 ClinVar Annotator: match by term: Hereditary cancer-predisposing syndrome ClinVar PMID:28492532 osteogenesis imperfecta type 17 ISO RGD:731035 8554872 ClinVar Annotator: match by term: Osteogenesis imperfecta, type xvii ClinVar PMID:26027498
Imported Annotations - CTD
acute myeloid leukemia ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:18206229 adrenocortical carcinoma ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:22156929 Colonic Neoplasms ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:17397030 Colorectal Neoplasms ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:18458674 degenerative disc disease ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:20714283 Experimental Liver Cirrhosis ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism, therapeutic CTD PMID:18615449 , PMID:25380136 Experimental Neoplasms ISO RGD:731035 11554173 CTD Direct Evidence: therapeutic CTD PMID:20164124 hepatitis ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:23408952 Hyperalgesia ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:20714283 kidney disease ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:12660331 liver cirrhosis ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:23408952 Low Back Pain ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:20714283 multiple myeloma ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:18172295 Myocardial Ischemia ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:16214533 Necrosis ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:23408952 osteogenesis imperfecta ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:1793673 Ovarian Neoplasms ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:19177197 thrombocytopenia ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:27725143 uremia ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:19092814 Weight Gain ISO RGD:731035 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:19030233 Imported Annotations - OMIM
osteogenesis imperfecta type 17 ISO RGD:731035 7240710 OMIM
(R)-camphor affects expression ISO RGD:11336 6480464 Camphor analog affects the expression of SPARC mRNA CTD PMID:24704097 1,1-dichloroethene increases expression ISO RGD:11336 6480464 vinylidene chloride results in increased expression of SPARC mRNA CTD PMID:26682919 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine increases expression EXP 6480464 chlorcyclizine results in increased expression of SPARC mRNA CTD PMID:21058326 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of SPARC mRNA CTD PMID:25380136 17alpha-ethynylestradiol increases expression ISO RGD:11336 6480464 Ethinyl Estradiol results in increased expression of SPARC mRNA CTD PMID:17942748 17alpha-ethynylestradiol multiple interactions ISO RGD:11336 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SPARC mRNA CTD PMID:17942748 17alpha-ethynylestradiol decreases expression EXP 6480464 Ethinyl Estradiol results in decreased expression of SPARC mRNA CTD PMID:17557909 17alpha-ethynylestradiol affects expression EXP 6480464 Ethinyl Estradiol affects the expression of SPARC mRNA CTD PMID:16079270 17beta-estradiol multiple interactions ISO RGD:11336 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of SPARC mRNA CTD PMID:19693291 17beta-estradiol multiple interactions ISO RGD:731035 6480464 [Estradiol co-treated with TGFB1 protein] results in increased expression of SPARC mRNA CTD PMID:30165855 17beta-estradiol decreases expression ISO RGD:11336 6480464 Estradiol results in decreased expression of SPARC mRNA CTD PMID:19693291 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:11336 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SPARC mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:11336 6480464 Tetrachlorodibenzodioxin affects the expression of SPARC mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:731035 6480464 Tetrachlorodibenzodioxin results in decreased expression of SPARC mRNA CTD PMID:11489354 more ... 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of SPARC mRNA CTD PMID:11752688 2,4,6-trinitrobenzenesulfonic acid multiple interactions ISO RGD:11336 6480464 Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA] more ... CTD PMID:17994277 , PMID:18200517 2,4,6-trinitrobenzenesulfonic acid increases expression ISO RGD:11336 6480464 Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA CTD PMID:17994277 , PMID:18200517 3,3',4,4',5-pentachlorobiphenyl increases expression EXP 6480464 3 more ... CTD PMID:20959002 3H-1,2-dithiole-3-thione decreases expression EXP 6480464 1, 2-dithiol-3-thione results in decreased expression of SPARC mRNA CTD PMID:19162173 4,4'-diaminodiphenylmethane increases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in increased expression of SPARC mRNA CTD PMID:25380136 4,4'-diaminodiphenylmethane decreases expression ISO RGD:11336 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of SPARC mRNA CTD PMID:18648102 4,4'-sulfonyldiphenol multiple interactions ISO RGD:11336 6480464 [bis(4-hydroxyphenyl)sulfone co-treated with Tretinoin] results in decreased expression of SPARC mRNA CTD PMID:30951980 4,4'-sulfonyldiphenol increases expression ISO RGD:11336 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of SPARC mRNA CTD PMID:30951980 4-hydroxyphenyl retinamide decreases expression ISO RGD:11336 6480464 Fenretinide results in decreased expression of SPARC mRNA CTD PMID:28973697 5-aza-2'-deoxycytidine increases expression ISO RGD:731035 6480464 Decitabine results in increased expression of SPARC mRNA, Decitabine results in increased expression of SPARC protein CTD PMID:17397030 , PMID:19177197 5-aza-2'-deoxycytidine multiple interactions ISO RGD:731035 6480464 [Decitabine affects the methylation of SPARC promoter] which affects the expression of SPARC mRNA more ... CTD PMID:18458674 , PMID:19177197 5-fluorouracil multiple interactions ISO RGD:731035 6480464 [decitabine affects the methylation of SPARC promoter] which affects the susceptibility to Fluorouracil CTD PMID:18458674 5-fluorouracil affects expression ISO RGD:11336 6480464 Fluorouracil affects the expression of SPARC mRNA CTD PMID:24704097 5-fluorouracil increases response to substance ISO RGD:731035 6480464 SPARC protein results in increased susceptibility to Fluorouracil CTD PMID:15902309 acetylsalicylic acid multiple interactions ISO RGD:731035 6480464 Aspirin inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY analog results in increased secretion of SPARC protein] CTD PMID:17303692 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of SPARC mRNA CTD PMID:28959563 aldehydo-D-glucose multiple interactions ISO RGD:731035 6480464 cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of SPARC mRNA] CTD PMID:19924377 aldehydo-D-glucose decreases expression ISO RGD:731035 6480464 Glucose results in decreased expression of SPARC mRNA CTD PMID:19924377 alendronic acid affects expression EXP 6480464 Alendronate affects the expression of SPARC mRNA CTD PMID:16079270 all-trans-retinoic acid multiple interactions ISO RGD:11336 6480464 [bis(4-hydroxyphenyl)sulfone co-treated with Tretinoin] results in decreased expression of SPARC mRNA more ... CTD PMID:17994277 , PMID:30951980 all-trans-retinoic acid affects expression ISO RGD:11336 6480464 Tretinoin affects the expression of SPARC mRNA CTD PMID:24704097 all-trans-retinoic acid increases expression EXP 6480464 Tretinoin results in increased expression of SPARC mRNA CTD PMID:24977338 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of SPARC mRNA CTD PMID:16483693 amphetamine increases expression EXP 6480464 Amphetamine results in increased expression of SPARC mRNA CTD PMID:30779732 antirheumatic drug increases expression ISO RGD:731035 6480464 Antirheumatic Agents results in increased expression of SPARC mRNA CTD PMID:24449571 arachidonic acid decreases expression ISO RGD:731035 6480464 Arachidonic Acid results in decreased expression of SPARC mRNA CTD PMID:16704987 arsane affects methylation ISO RGD:731035 6480464 Arsenic affects the methylation of SPARC gene CTD PMID:25304211 arsenic atom affects methylation ISO RGD:731035 6480464 Arsenic affects the methylation of SPARC gene CTD PMID:25304211 arsenite(3-) decreases expression ISO RGD:731035 6480464 arsenite results in decreased expression of SPARC mRNA CTD PMID:23974009 arsenite(3-) increases methylation ISO RGD:731035 6480464 arsenite results in increased methylation of SPARC promoter CTD PMID:23974009 avobenzone increases expression ISO RGD:731035 6480464 avobenzone results in increased expression of SPARC mRNA CTD PMID:31016361 benzene multiple interactions EXP 6480464 [Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in decreased expression of SPARC mRNA CTD PMID:17905399 benzene decreases expression ISO RGD:731035 6480464 Benzene results in decreased expression of SPARC mRNA CTD PMID:19162166 benzo[a]pyrene increases expression ISO RGD:11336 6480464 Benzo(a)pyrene results in increased expression of SPARC mRNA CTD PMID:22610609 benzo[b]fluoranthene increases expression ISO RGD:11336 6480464 benzo(b)fluoranthene results in increased expression of SPARC mRNA CTD PMID:26377693 berberine increases expression ISO RGD:731035 6480464 Berberine results in increased expression of SPARC mRNA CTD PMID:26478571 bexarotene increases expression ISO RGD:731035 6480464 bexarotene results in increased expression of SPARC mRNA CTD PMID:17178900 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of SPARC mRNA, bisphenol A affects the expression of SPARC protein CTD PMID:20219716 , PMID:25181051 bisphenol A increases expression ISO RGD:731035 6480464 bisphenol A results in increased expression of SPARC mRNA CTD PMID:31715268 bisphenol A increases expression ISO RGD:11336 6480464 bisphenol A results in increased expression of SPARC mRNA CTD PMID:30951980 bisphenol A decreases expression ISO RGD:731035 6480464 bisphenol A results in decreased expression of SPARC mRNA CTD PMID:29275510 bisphenol A affects expression ISO RGD:731035 6480464 bisphenol A affects the expression of SPARC mRNA CTD PMID:30903817 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of SPARC mRNA, bisphenol A results in decreased expression of SPARC protein CTD PMID:20219716 , PMID:30816183 bisphenol F increases expression ISO RGD:11336 6480464 bisphenol F results in increased expression of SPARC mRNA CTD PMID:30951980 bisphenol F multiple interactions ISO RGD:11336 6480464 [bisphenol F co-treated with Tretinoin] results in decreased expression of SPARC mRNA CTD PMID:30951980 bleomycin A2 increases response to substance ISO RGD:11336 6480464 SPARC protein results in increased susceptibility to Bleomycin CTD PMID:19446018 boric acid affects expression ISO RGD:11336 6480464 boric acid affects the expression of SPARC mRNA CTD PMID:24704097 buspirone decreases expression EXP 6480464 Buspirone results in decreased expression of SPARC mRNA CTD PMID:24136188 cadmium atom decreases expression ISO RGD:731035 6480464 Cadmium results in decreased expression of SPARC mRNA CTD PMID:20570719 , PMID:31082426 cadmium atom multiple interactions ISO RGD:731035 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SPARC mRNA CTD PMID:29741670 cadmium atom increases expression EXP 6480464 Cadmium results in increased expression of SPARC mRNA CTD PMID:9232954 cadmium dichloride decreases expression ISO RGD:731035 6480464 Cadmium Chloride results in decreased expression of SPARC mRNA, Cadmium Chloride results in decreased expression of SPARC protein CTD PMID:20837119 cadmium dichloride multiple interactions ISO RGD:731035 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SPARC mRNA CTD PMID:29741670 calciol multiple interactions ISO RGD:731035 6480464 [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein CTD PMID:17692823 calcitriol increases expression EXP 6480464 Calcitriol results in increased expression of SPARC protein CTD PMID:19092814 camphor affects expression ISO RGD:11336 6480464 Camphor analog affects the expression of SPARC mRNA CTD PMID:24704097 carbamazepine affects expression ISO RGD:731035 6480464 Carbamazepine affects the expression of SPARC mRNA CTD PMID:25979313 carbon nanotube decreases expression ISO RGD:11336 6480464 Nanotubes, Carbon analog results in decreased expression of SPARC mRNA CTD PMID:25620056 carmustine affects response to substance ISO RGD:731035 6480464 SPARC mRNA affects the susceptibility to Carmustine CTD PMID:16365179 casticin increases expression ISO RGD:11336 6480464 casticin results in increased expression of SPARC mRNA CTD PMID:28444820 casticin decreases expression ISO RGD:731035 6480464 casticin results in decreased expression of SPARC mRNA CTD PMID:27862857 chlorpyrifos decreases expression ISO RGD:11336 6480464 Chlorpyrifos results in decreased expression of SPARC mRNA CTD PMID:20350560 choline multiple interactions ISO RGD:11336 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SPARC mRNA CTD PMID:20938992 cisplatin multiple interactions ISO RGD:731035 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of SPARC mRNA, [Cisplatin co-treated with Paclitaxel] results in decreased expression of SPARC mRNA CTD PMID:20705681 , PMID:27392435 cisplatin decreases expression ISO RGD:731035 6480464 Cisplatin results in decreased expression of SPARC mRNA CTD PMID:27392435 copper atom multiple interactions ISO RGD:11336 6480464 [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPARC mRNA CTD PMID:15467011 copper atom decreases expression EXP 6480464 Copper results in decreased expression of SPARC mRNA CTD PMID:30556269 copper atom increases expression ISO RGD:11336 6480464 Copper results in increased expression of SPARC mRNA CTD PMID:16629173 copper atom decreases secretion ISO RGD:11336 6480464 Copper results in decreased secretion of SPARC protein CTD PMID:19635393 copper(0) multiple interactions ISO RGD:11336 6480464 [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPARC mRNA CTD PMID:15467011 copper(0) decreases expression EXP 6480464 Copper results in decreased expression of SPARC mRNA CTD PMID:30556269 copper(0) increases expression ISO RGD:11336 6480464 Copper results in increased expression of SPARC mRNA CTD PMID:16629173 copper(0) decreases secretion ISO RGD:11336 6480464 Copper results in decreased secretion of SPARC protein CTD PMID:19635393 crocidolite asbestos multiple interactions ISO RGD:11336 6480464 Asbestos, Crocidolite inhibits the reaction [SPARC gene mutant form results in decreased expression of SFTPC mRNA] more ... CTD PMID:19446018 crocidolite asbestos increases response to substance ISO RGD:11336 6480464 SPARC protein results in increased susceptibility to Asbestos, Crocidolite CTD PMID:19446018 curcumin multiple interactions ISO RGD:11336 6480464 Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA] CTD PMID:18200517 cyclophosphamide decreases expression ISO RGD:11336 6480464 Cyclophosphamide results in decreased expression of SPARC mRNA CTD PMID:15331540 cyclophosphamide increases expression ISO RGD:731035 6480464 Cyclophosphamide results in increased expression of SPARC mRNA CTD PMID:17403535 cyclosporin A decreases expression ISO RGD:731035 6480464 Cyclosporine results in decreased expression of SPARC mRNA CTD PMID:20106945 , PMID:25562108 cytarabine decreases expression ISO RGD:731035 6480464 Cytarabine results in decreased expression of SPARC mRNA CTD PMID:21198554 D-glucose decreases expression ISO RGD:731035 6480464 Glucose results in decreased expression of SPARC mRNA CTD PMID:19924377 D-glucose multiple interactions ISO RGD:731035 6480464 cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of SPARC mRNA] CTD PMID:19924377 DDT increases expression ISO RGD:731035 6480464 DDT results in increased expression of SPARC mRNA CTD PMID:25014179 dexamethasone decreases expression EXP 6480464 Dexamethasone results in decreased expression of SPARC mRNA CTD PMID:9232954 dextran sulfate multiple interactions ISO RGD:11336 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPARC mRNA CTD PMID:29950665 dioxygen increases expression ISO RGD:11336 6480464 Oxygen deficiency results in increased expression of SPARC mRNA CTD PMID:28174749 dioxygen multiple interactions ISO RGD:11336 6480464 GPR68 protein affects the reaction [Oxygen deficiency results in increased expression of SPARC mRNA] CTD PMID:28174749 diuron decreases expression EXP 6480464 Diuron results in decreased expression of SPARC mRNA CTD PMID:25152437 diuron increases expression EXP 6480464 Diuron results in increased expression of SPARC mRNA CTD PMID:21551480 dorsomorphin multiple interactions ISO RGD:731035 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPARC mRNA CTD PMID:27188386 doxorubicin increases expression ISO RGD:731035 6480464 Doxorubicin results in increased expression of SPARC mRNA CTD PMID:15870702 doxorubicin decreases expression ISO RGD:731035 6480464 Doxorubicin results in decreased expression of SPARC mRNA CTD PMID:29803840 doxorubicin increases expression ISO RGD:11336 6480464 Doxorubicin results in increased expression of SPARC mRNA CTD PMID:15033991 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of SPARC mRNA CTD PMID:29391264 ethanol increases expression ISO RGD:731035 6480464 Ethanol results in increased expression of SPARC mRNA CTD PMID:15963989 ethanol increases expression ISO RGD:11336 6480464 Ethanol results in increased expression of SPARC mRNA CTD PMID:30319688 fenamidone increases expression ISO RGD:11336 6480464 fenamidone results in increased expression of SPARC mRNA CTD PMID:27029645 folic acid multiple interactions ISO RGD:11336 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SPARC mRNA CTD PMID:20938992 formaldehyde decreases expression ISO RGD:731035 6480464 Formaldehyde results in decreased expression of SPARC mRNA CTD PMID:23649840 fulvestrant multiple interactions ISO RGD:731035 6480464 fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of SPARC mRNA] CTD PMID:26362186 furan increases expression EXP 6480464 furan results in increased expression of SPARC mRNA CTD PMID:27387713 furosemide increases expression EXP 6480464 Furosemide results in increased expression of SPARC mRNA CTD PMID:16526316 gallocatechin increases expression EXP 6480464 gallocatechol results in increased expression of SPARC mRNA CTD PMID:21877759 gamma-aminobutyric acid affects expression EXP 6480464 gamma-Aminobutyric Acid affects the expression of SPARC mRNA CTD PMID:24098073 gamma-Oryzanol (TN) affects expression EXP 6480464 gamma-oryzanol affects the expression of SPARC mRNA CTD PMID:24098073 genistein increases expression EXP 6480464 Genistein results in increased expression of SPARC mRNA CTD PMID:21877759 glucose decreases expression ISO RGD:731035 6480464 Glucose results in decreased expression of SPARC mRNA CTD PMID:19924377 glucose multiple interactions ISO RGD:731035 6480464 cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of SPARC mRNA] CTD PMID:19924377 glycerol 2-phosphate multiple interactions ISO RGD:731035 6480464 [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein CTD PMID:17692823 indometacin multiple interactions ISO RGD:11336 6480464 Indomethacin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA] CTD PMID:17994277 isoflavones affects expression ISO RGD:731035 6480464 Isoflavones affects the expression of SPARC mRNA CTD PMID:16365062 L-ascorbic acid multiple interactions ISO RGD:731035 6480464 [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein CTD PMID:17692823 L-methionine multiple interactions ISO RGD:11336 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SPARC mRNA CTD PMID:20938992 lipopolysaccharide increases expression ISO RGD:11336 6480464 Lipopolysaccharides results in increased expression of SPARC mRNA CTD PMID:27339419 losartan decreases expression EXP 6480464 Losartan results in decreased expression of SPARC mRNA CTD PMID:15100363 magnesium atom increases expression ISO RGD:731035 6480464 Magnesium results in increased expression of SPARC protein CTD PMID:10397942 methyl methanesulfonate decreases expression ISO RGD:731035 6480464 Methyl Methanesulfonate results in decreased expression of SPARC mRNA CTD PMID:23649840 methylmercury chloride decreases expression ISO RGD:731035 6480464 methylmercuric chloride results in decreased expression of SPARC mRNA CTD PMID:23179753 methylmercury(1+) increases expression EXP 6480464 methylmercury II results in increased expression of SPARC mRNA CTD PMID:17905399 methylmercury(1+) multiple interactions EXP 6480464 [Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in decreased expression of SPARC mRNA CTD PMID:17905399 N-ethyl-N-nitrosourea increases expression EXP 6480464 Ethylnitrosourea results in increased expression of SPARC mRNA CTD PMID:15954086 N-methyl-4-phenylpyridinium decreases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of SPARC mRNA CTD PMID:28801915 N-methyl-N'-nitro-N-nitrosoguanidine decreases expression ISO RGD:731035 6480464 Methylnitronitrosoguanidine results in decreased expression of SPARC mRNA CTD PMID:12634122 N-nitrosodiethylamine increases expression EXP 6480464 Diethylnitrosamine results in increased expression of SPARC mRNA CTD PMID:19638242 N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in increased expression of SPARC mRNA CTD PMID:28943392 N-nitrosodiethylamine increases expression ISO RGD:11336 6480464 Diethylnitrosamine results in increased expression of SPARC mRNA CTD PMID:24535843 N-nitrosodimethylamine increases expression EXP 6480464 Dimethylnitrosamine results in increased expression of SPARC mRNA CTD PMID:25380136 nefazodone decreases expression EXP 6480464 nefazodone results in decreased expression of SPARC mRNA CTD PMID:24136188 nimesulide decreases expression EXP 6480464 nimesulide results in decreased expression of SPARC mRNA CTD PMID:24136188 notoginsenoside R1 multiple interactions ISO RGD:731035 6480464 fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of SPARC mRNA] CTD PMID:26362186 notoginsenoside R1 increases expression ISO RGD:731035 6480464 notoginsenoside R1 results in increased expression of SPARC mRNA CTD PMID:26362186 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of SPARC mRNA CTD PMID:25729387 oxaliplatin increases expression EXP 6480464 oxaliplatin results in increased expression of SPARC mRNA CTD PMID:25729387 p-toluidine decreases expression EXP 6480464 4-toluidine results in decreased expression of SPARC mRNA CTD PMID:27638505 paclitaxel multiple interactions ISO RGD:731035 6480464 [Cisplatin co-treated with Paclitaxel] results in decreased expression of SPARC mRNA CTD PMID:20705681 paclitaxel increases expression ISO RGD:731035 6480464 Paclitaxel results in increased expression of SPARC mRNA CTD PMID:19682730 palbociclib increases expression ISO RGD:731035 6480464 palbociclib results in increased expression of SPARC mRNA CTD PMID:28620137 paracetamol affects expression ISO RGD:11336 6480464 Acetaminophen affects the expression of SPARC mRNA CTD PMID:17562736 paracetamol decreases expression ISO RGD:731035 6480464 Acetaminophen results in decreased expression of SPARC mRNA CTD PMID:29067470 perfluorooctane-1-sulfonic acid affects expression ISO RGD:731035 6480464 perfluorooctane sulfonic acid affects the expression of SPARC mRNA CTD PMID:30738844 phenobarbital affects expression ISO RGD:731035 6480464 Phenobarbital affects the expression of SPARC mRNA CTD PMID:19159669 phenylmercury acetate increases expression ISO RGD:731035 6480464 Phenylmercuric Acetate results in increased expression of SPARC mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:731035 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPARC mRNA CTD PMID:27188386 piroxicam decreases expression ISO RGD:731035 6480464 Piroxicam results in decreased expression of SPARC mRNA CTD PMID:21858171 poly(vinylpyrrolidone) multiple interactions EXP 6480464 [Silver analog co-treated with Povidone] results in decreased expression of SPARC mRNA CTD PMID:25194297 potassium dichromate increases expression ISO RGD:11336 6480464 Potassium Dichromate results in increased expression of SPARC mRNA CTD PMID:23608068 progesterone multiple interactions ISO RGD:11336 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of SPARC mRNA CTD PMID:19693291 raloxifene affects expression EXP 6480464 Raloxifene Hydrochloride affects the expression of SPARC mRNA CTD PMID:16079270 resveratrol decreases expression ISO RGD:731035 6480464 resveratrol results in decreased expression of SPARC mRNA, resveratrol results in decreased expression of SPARC protein CTD PMID:16084059 resveratrol decreases expression EXP 6480464 resveratrol results in decreased expression of SPARC mRNA CTD PMID:19228061 rotenone affects expression EXP 6480464 Rotenone affects the expression of SPARC mRNA CTD PMID:28374803 SB 431542 multiple interactions ISO RGD:731035 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPARC mRNA CTD PMID:27188386 serpentine asbestos decreases expression ISO RGD:731035 6480464 Asbestos, Serpentine results in decreased expression of SPARC mRNA CTD PMID:21148743 silicon dioxide decreases expression EXP 6480464 Silicon Dioxide results in decreased expression of SPARC mRNA CTD PMID:22431001 silver atom multiple interactions EXP 6480464 [Silver analog co-treated with Povidone] results in decreased expression of SPARC mRNA CTD PMID:25194297 silver(0) multiple interactions EXP 6480464 [Silver analog co-treated with Povidone] results in decreased expression of SPARC mRNA CTD PMID:25194297 sodium arsenite multiple interactions ISO RGD:731035 6480464 [sodium arsenite affects the acetylation of H3-4 protein] which affects the methylation of SPARC promoter CTD PMID:18448484 sodium arsenite increases expression ISO RGD:731035 6480464 sodium arsenite results in increased expression of SPARC mRNA CTD PMID:20371982 sodium arsenite decreases expression ISO RGD:731035 6480464 sodium arsenite results in decreased expression of SPARC mRNA, sodium arsenite results in decreased expression of SPARC protein CTD PMID:20837119 sodium arsenite decreases expression ISO RGD:11336 6480464 sodium arsenite results in decreased expression of SPARC mRNA CTD PMID:18812580 sodium fluoride increases expression EXP 6480464 Sodium Fluoride results in increased expression of SPARC mRNA CTD PMID:24300170 sodium fluoride multiple interactions EXP 6480464 DKK1 protein inhibits the reaction [Sodium Fluoride results in increased expression of SPARC mRNA] CTD PMID:24300170 Soman increases expression EXP 6480464 Soman results in increased expression of SPARC mRNA CTD PMID:19281266 streptozocin increases expression ISO RGD:11336 6480464 Streptozocin results in increased expression of SPARC mRNA, Streptozocin results in increased expression of SPARC protein CTD PMID:12660331 sunitinib decreases expression ISO RGD:731035 6480464 Sunitinib results in decreased expression of SPARC mRNA CTD PMID:31533062 temozolomide affects response to substance ISO RGD:731035 6480464 SPARC mRNA affects the susceptibility to temozolomide CTD PMID:16365179 tert-butyl hydroperoxide decreases expression ISO RGD:731035 6480464 tert-Butylhydroperoxide results in decreased expression of SPARC mRNA CTD PMID:15336504 tert-butyl hydroperoxide increases expression ISO RGD:731035 6480464 tert-Butylhydroperoxide results in increased expression of SPARC mRNA CTD PMID:15963989 testosterone increases expression ISO RGD:11336 6480464 Testosterone results in increased expression of SPARC mRNA CTD PMID:19693291 tetrachloromethane affects expression ISO RGD:11336 6480464 Carbon Tetrachloride affects the expression of SPARC mRNA CTD PMID:17484886 tetrachloromethane increases expression ISO RGD:11336 6480464 Carbon Tetrachloride results in increased expression of SPARC mRNA CTD PMID:27339419 , PMID:29987408 tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of SPARC mRNA CTD PMID:16239168 , PMID:17056239 thioacetamide affects response to substance ISO RGD:11336 6480464 SPARC protein affects the susceptibility to Thioacetamide CTD PMID:23408952 thioacetamide multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in increased expression of SPARC mRNA CTD PMID:28943392 thioacetamide multiple interactions ISO RGD:11336 6480464 SPARC protein affects the reaction [Thioacetamide results in increased expression of COL1A2 mRNA] more ... CTD PMID:23408952 thioacetamide increases expression ISO RGD:11336 6480464 Thioacetamide results in increased expression of SPARC mRNA CTD PMID:23408952 titanium dioxide decreases expression ISO RGD:11336 6480464 titanium dioxide results in decreased expression of SPARC mRNA CTD PMID:23557971 titanium dioxide multiple interactions ISO RGD:11336 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPARC mRNA CTD PMID:29950665 topotecan increases expression EXP 6480464 Topotecan results in increased expression of SPARC mRNA CTD PMID:25729387 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of SPARC mRNA CTD PMID:25729387 Trapidil multiple interactions EXP 6480464 Trapidil affects the reaction [PTH protein affects the expression of SPARC mRNA] CTD PMID:18635661 triacsin C decreases expression ISO RGD:731035 6480464 triacsin C results in decreased expression of SPARC mRNA CTD PMID:16704987 trichloroethene multiple interactions EXP 6480464 [Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in decreased expression of SPARC mRNA CTD PMID:17905399 trichloroethene increases expression EXP 6480464 Trichloroethylene results in increased expression of SPARC mRNA CTD PMID:19448997 triclosan increases expression ISO RGD:731035 6480464 Triclosan results in increased expression of SPARC mRNA CTD PMID:30510588 valproic acid affects expression ISO RGD:11336 6480464 Valproic Acid affects the expression of SPARC mRNA CTD PMID:17963808 valproic acid increases expression ISO RGD:731035 6480464 Valproic Acid results in increased expression of SPARC mRNA CTD PMID:23179753 , PMID:27188386 valproic acid affects expression ISO RGD:731035 6480464 Valproic Acid affects the expression of SPARC mRNA CTD PMID:25979313 valproic acid decreases expression ISO RGD:731035 6480464 Valproic Acid results in decreased expression of SPARC mRNA CTD PMID:23179753 , PMID:29154799 vancomycin decreases expression ISO RGD:11336 6480464 Vancomycin results in decreased expression of SPARC mRNA CTD PMID:18930951
Gene-Chemical Interaction Annotations
